Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you counsel and manage joint pain after isotretinoin treatment?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach treatment of SAPHO syndrome?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
